Compare MOVE & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOVE | ANAB |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2021 | 2015 |
| Metric | MOVE | ANAB |
|---|---|---|
| Price | $14.70 | $56.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $71.67 |
| AVG Volume (30 Days) | 45.5K | ★ 640.4K |
| Earning Date | 04-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | N/A | ★ N/A |
| Revenue | $433,000.00 | ★ $234,603,000.00 |
| Revenue This Year | $1,460.71 | N/A |
| Revenue Next Year | $96.77 | $52.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $0.52 | $17.11 |
| 52 Week High | $34.87 | $73.30 |
| Indicator | MOVE | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 38.07 | 42.37 |
| Support Level | $11.63 | $52.32 |
| Resistance Level | $15.51 | $57.70 |
| Average True Range (ATR) | 2.69 | 4.64 |
| MACD | -0.66 | -0.40 |
| Stochastic Oscillator | 5.50 | 13.02 |
Corvex Inc is an AI cloud computing company that provides computing infrastructure for artificial intelligence workloads, including GPU-accelerated computing, confidential computing, and inference services. Its offerings are used by government and enterprise customers, including those with regulated workloads, to support the deployment and operation of AI models and data processing systems. The company generates revenue from the sale of Wellness Rings, portable chargers and charging cables, ring sizers, and mobile applications.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).